These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31398658)

  • 1. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
    Cortese A; Lucchetti R; Altobelli A; Conte A; Primavera M; Valesini G; Millefiorini E; Scrivo R
    Mult Scler Relat Disord; 2019 Oct; 35():193-195. PubMed ID: 31398658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
    Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of secukinumab for the treatment of active ankylosing spondylitis.
    Loricera J; Galíndez-Aguirregoikoa E; Blanco R
    Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
    [No Abstract]   [Full Text] [Related]  

  • 4. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
    Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
    Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
    Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
    Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.
    Psarelis S; Hajineocli APD; Hadjicosta E; Elliott HSA; Johnson P
    Clin Rheumatol; 2017 May; 36(5):1197-1199. PubMed ID: 28233109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
    Nisar MK
    Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
    [No Abstract]   [Full Text] [Related]  

  • 8. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
    RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.
    Wendling D; Verhoeven F; Prati C
    Expert Opin Biol Ther; 2019 Jan; 19(1):55-64. PubMed ID: 30500270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
    J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
    Braun J; Baraliakos X; Kiltz U
    Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept for Ankylosing Spondylitis With Coexisting Demyelinating Myelitis.
    Ye C; Geng Z; Li S; Yu F
    Am J Ther; 2019; 26(5):e629-e631. PubMed ID: 30199382
    [No Abstract]   [Full Text] [Related]  

  • 14. Secukinumab: A Review in Ankylosing Spondylitis.
    Blair HA; Dhillon S
    Drugs; 2016 Jul; 76(10):1023-30. PubMed ID: 27255593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
    Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
    Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
    [No Abstract]   [Full Text] [Related]  

  • 16. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.
    Purmonen T; Törmälehto S; Wahlman H; Puolakka K
    J Med Econ; 2019 Feb; 22(2):151-157. PubMed ID: 30474450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
    Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M; Taniguchi A; Fujishige A; Kaneko S; Haemmerle S; Porter BO; Kobayashi S
    Mod Rheumatol; 2020 Jan; 30(1):132-140. PubMed ID: 30334633
    [No Abstract]   [Full Text] [Related]  

  • 20. Secukinumab: A Review in Ankylosing Spondylitis.
    Blair HA
    Drugs; 2019 Mar; 79(4):433-443. PubMed ID: 30793255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.